EGFR
All Product Categories
-
EGFR Inhibitors
(574)
View all products
-
EGFR Agonists
(2)
View all products
-
EGFR Antagonist
(1)
View all products
-
EGFR Activators
(5)
View all products
-
EGFR Modulators
(5)
View all products
-
EGFR Chemicals
(3)
View all products
-
EGFR Inducers
(3)
View all products
-
EGFR Degraders
(21)
View all products
-
EGFR Controls
(6)
View all products
-
EGFR Substrate
(1)
View all products
-
EGFR Ligands
(12)
View all products
-
EGFR Related Products (748)
Related Products (748)
-
Trastuzumab deruxtecan
0 ImagesSynonyms: T-DXd; DS-8201; DS-8201aTrastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer.
-
Trastuzumab deruxtecan (solution)
0 ImagesSynonyms: T-DXd (solution); DS-8201 (solution); DS-8201a (solution)Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer.
-
Amivantamab
0 ImagesSynonyms: JNJ-61186372Amivantamab (JNJ-61186372) is a human EGFR-MET bispecific antibody with immune anticancer activity. Amivantamab inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells.
-
Trastuzumab emtansine
0 ImagesSynonyms: Ado-Trastuzumab emtansine; PRO132365; T-DM 1Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (HY-19792). Trastuzumab emtansine can be used for the research of advanced breast cancer.
-
Panitumumab
0 ImagesSynonyms: ABX-EGF
-
Anti-Human/Mouse Amphiregulin Antibody (AR37)
0 ImagesCat. No.: HY-P991748Purity: 99.544%Anti-Human/Mouse Amphiregulin Antibody (AR37) reacts with human and mouse amphiregulin (AREG) that can block AREG-induced activation of EGFR. Anti-Human/Mouse Amphiregulin Antibody (AR37) can prolong the survival and inhibit the growth of ovarian, breast, and prostate cancer models expressing AREG.
-
4,7-Dihydroxycoumarin
0 Images4,7-Dihydroxycoumarin is an EGFR inhibitor, estrogen receptor inhibitor, and progesterone receptor inhibitor. 4,7-Dihydroxycoumarin against breast cancer cells with an IC50 velue of 18.36 μg/mL. 4,7-Dihydroxycoumarin can be used for the research of breast cancer.
-
Firmonertinib-d3 mesylate
0 ImagesCat. No.: HY-112870ASPurity: 99.00%Synonyms: Alflutinib-d3 mesylate; Furmonertinib-d3 mesylate; AST2818-d3 mesylateFirmonertinib-d3 (Alflutinib-d3) mesylate is the deuterium labeled Firmonertinib mesylate (HY-112870A). Firmonertinib (Alflutinib; Furmonertinib) mesylate is is an orally active, mutant-selective, and blood-brain barrier penetrant EGFR inhibitor. Firmonertinib mesylate inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Firmonertinib mesylate has the potential for the research of cancer diseases, especially advanced non-small cell lung cancer (NSCLC) with EGFR ex20ins mutation.
-
Trastuzumab (anti-HER2)
0 ImagesSynonyms: Anti-Human HER2, Humanized Antibody (anti-HER2)
-
PACAP (1-38), human, ovine, rat
0 ImagesSynonyms: Pituitary Adenylate Cyclase Activating Polypeptide 38PACAP (1-38), human, ovine, rat is a PAC1 receptor agonist. PACAP (1-38), human, ovine, rat binds to PACAP type I receptor, PACAP type II receptor VIP1, and PACAP type II receptor VIP2 with IC50s of 4 nM, 2 nM, and 1 nM, respectively. PACAP (1-38), human, ovine, rat increases the α-secretase activity. PACAP (1-38), human, ovine, rat elevates cytosolic Ca2+, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP (1-38), human, ovine, rat demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP (1-38), human, ovine, rat can be used for neurotrophic and neuroprotective research.
-
Patritumab
0 ImagesSynonyms: AMG-888; U3-1287Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors.
-
Candidalysin
0 ImagesCandidalysin is a cytolytic peptide toxin secreted by the fungus Candida albicans. Candidalysin drives epithelial immune responses by activating the EGFR-MAPK signaling pathway, inducing MMP expression and calcium influx, and regulating the c-Fos transcription factor and MKP1 via p38 MAPK and ERK1/2 respectively. Candidalysin is essential for mucosal and systemic infections, activating NLRP3 to promote inflammatory responses, neutrophil recruitment, and Th17 immunity. Candidalysin activates LDH causing membrane damage and exhibiting cytotoxicity
-
Trastuzumab emtansine (solution)
0 ImagesSynonyms: Ado-Trastuzumab emtansine (solution); PRO132365 (solution); T-DM 1 (solution)Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine), and the drug-linker conjugate for ADC is SMCC-DM1 (HY-101070). Trastuzumab emtansine can be used for the research of advanced breast cancer.
-
Trastuzumab vedotin
0 ImagesCat. No.: HY-164992Purity: 98.05%Synonyms: MRG002; Trastuzumab MMAETrastuzumab vedotin (MRG002; Trastuzumab MMAE) is an antibody-drug conjugate and cytotoxin targeting HER2, with a Kd of 7.50E-11 M for human HER2. After binding to HER2, Trastuzumab vedotin undergoes internalization and lysosomal trafficking, delivering a cytotoxic payload to HER2-expressing cells and inducing tumor regression in in vivo xenograft models with HER2-expressing tumors. The anti-tumor activity of Trastuzumab vedotin is enhanced when used in combination with anti-PD-1 antibodies, and it exhibits preclinical anti-tumor activity in drug-resistant breast cancer, gastric cancer, and urothelial carcinoma PDX models. Trastuzumab vedotin has low antibody-dependent cellular cytotoxicity activity and can be used in studies related to HER2-positive breast cancer, HER2-positive gastric cancer, and unresectable locally advanced or metastatic HER2-positive urothelial carcinoma.
-
Nimotuzumab
0 ImagesCat. No.: HY-P9968CAS No.: 780758-10-3Synonyms: h-R3Nimotuzumab is a humanized IgG1 monoclonal antibody targeting EGFR with a KD of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab, a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC).
-
Runimotamab
0 ImagesSynonyms: BTRC-4017A; RG-6194
